Literature DB >> 18181733

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.

Sonia Gutiérrez1, Silvia Guillemi, Natalie Jahnke, Valentina Montessori, P Richard Harrigan, Julio S G Montaner.   

Abstract

We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy. In all cases, the introduction of tenofovir led to a sustained undetectable HBV and HIV loads, with marked clinical and laboratory improvement in liver function. We provide supporting evidence for the role of tenofovir in the management of advanced HBV infection in HIV-positive patients after the development of lamivudine resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181733     DOI: 10.1086/525857

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

2.  New approaches in the management of chronic hepatitis B: role of tenofovir.

Authors:  Jurriën Gp Reijnders; Harry LA Janssen
Journal:  Infect Drug Resist       Date:  2009-04-24       Impact factor: 4.003

3.  Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Authors:  Erik De Clercq; Geoffrey Férir; Suzanne Kaptein; Johan Neyts
Journal:  Viruses       Date:  2010-05-31       Impact factor: 5.818

4.  Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.

Authors:  Yu-Shan Huang; Sui-Yuan Chang; Wang-Huei Sheng; Hsin-Yun Sun; Kuan-Yeh Lee; Yu-Chung Chuang; Yi-Ching Su; Wen-Chun Liu; Chien-Ching Hung; Shan-Chwen Chang
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

5.  Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.

Authors:  Cho Naing; Yong Poovorawan; Kew Siang Tong
Journal:  BMC Infect Dis       Date:  2018-11-14       Impact factor: 3.090

6.  Tenofovir and its potential in the treatment of hepatitis B virus.

Authors:  Laura Reynaud; Maria Aurora Carleo; Maria Talamo; Guglielmo Borgia
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

Review 7.  Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.

Authors:  Huw Price; David Dunn; Deenan Pillay; Firouze Bani-Sadr; Theodora de Vries-Sluijs; Mamta K Jain; Noriyoshi Kuzushita; Stefan Mauss; Marina Núñez; Reto Nüesch; Marion Peters; Thomas Reiberger; Christoph Stephan; Lionel Tan; Richard Gilson
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.